Anti-platelet agregation: what did we learn from the evidence?
Hyperglycemia and insulin resistance, characteristics of patients with type 2 diabetes mellitus (T2D), produce platelet and endothelial alterations, increasing the risk of thrombotic events. The efficacy and benefit of antiplatelet therapy are well established in patients with atherosclerotic cardio...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Sello Editorial Lugones
2022-09-01
|
| Series: | Revista de la Sociedad Argentina de Diabetes |
| Subjects: | |
| Online Access: | https://revistasad.com/index.php/diabetes/article/view/595 |
| _version_ | 1797983977274867712 |
|---|---|
| author | Augusto Lavalle Cobo |
| author_facet | Augusto Lavalle Cobo |
| author_sort | Augusto Lavalle Cobo |
| collection | DOAJ |
| description | Hyperglycemia and insulin resistance, characteristics of patients with type 2 diabetes mellitus (T2D), produce platelet and endothelial alterations, increasing the risk of thrombotic events. The efficacy and benefit of antiplatelet therapy are well established in patients with atherosclerotic cardiovascular disease. There is little discussion about the combination of low doses of acetylsalicylic acid (ASA) and a P2Y12 receptor inhibitor in the acute setting of a cardiovascular event. Current evidence seeks to answer the question of how long to maintain this double regimen, mainly in patients with a high risk of bleeding. Maintaining dual antiplatelet therapy for at least one year is recommended after an acute event.This time could be shortened for patients with high bleeding risk and extended for a longer period in patients with a high thrombotic risk. In this scenario, rivaroxaban 2.5 mg b.i.d, can be considered. |
| first_indexed | 2024-04-11T06:55:40Z |
| format | Article |
| id | doaj.art-50efca726e8242b49ee49ecb82278d68 |
| institution | Directory Open Access Journal |
| issn | 0325-5247 2346-9420 |
| language | Spanish |
| last_indexed | 2024-04-11T06:55:40Z |
| publishDate | 2022-09-01 |
| publisher | Sello Editorial Lugones |
| record_format | Article |
| series | Revista de la Sociedad Argentina de Diabetes |
| spelling | doaj.art-50efca726e8242b49ee49ecb82278d682022-12-22T04:39:03ZspaSello Editorial LugonesRevista de la Sociedad Argentina de Diabetes0325-52472346-94202022-09-01563Sup565610.47196/diab.v56i3Sup.595509Anti-platelet agregation: what did we learn from the evidence?Augusto Lavalle Cobo0Especialista en Cardiología, Coordinador del Servicio de Cardiología, Sanatorio Finochietto, Ciudad Autónoma de Buenos Aires, ArgentinaHyperglycemia and insulin resistance, characteristics of patients with type 2 diabetes mellitus (T2D), produce platelet and endothelial alterations, increasing the risk of thrombotic events. The efficacy and benefit of antiplatelet therapy are well established in patients with atherosclerotic cardiovascular disease. There is little discussion about the combination of low doses of acetylsalicylic acid (ASA) and a P2Y12 receptor inhibitor in the acute setting of a cardiovascular event. Current evidence seeks to answer the question of how long to maintain this double regimen, mainly in patients with a high risk of bleeding. Maintaining dual antiplatelet therapy for at least one year is recommended after an acute event.This time could be shortened for patients with high bleeding risk and extended for a longer period in patients with a high thrombotic risk. In this scenario, rivaroxaban 2.5 mg b.i.d, can be considered.https://revistasad.com/index.php/diabetes/article/view/595antiagregación plaquetariatratamiento |
| spellingShingle | Augusto Lavalle Cobo Anti-platelet agregation: what did we learn from the evidence? Revista de la Sociedad Argentina de Diabetes antiagregación plaquetaria tratamiento |
| title | Anti-platelet agregation: what did we learn from the evidence? |
| title_full | Anti-platelet agregation: what did we learn from the evidence? |
| title_fullStr | Anti-platelet agregation: what did we learn from the evidence? |
| title_full_unstemmed | Anti-platelet agregation: what did we learn from the evidence? |
| title_short | Anti-platelet agregation: what did we learn from the evidence? |
| title_sort | anti platelet agregation what did we learn from the evidence |
| topic | antiagregación plaquetaria tratamiento |
| url | https://revistasad.com/index.php/diabetes/article/view/595 |
| work_keys_str_mv | AT augustolavallecobo antiplateletagregationwhatdidwelearnfromtheevidence |